美国制药巨头辉瑞(Pfizer)口服靶向抗癌药Xalkori(crizotinib,克唑替尼)近日在英国监管方面迎来转机。英国医疗成本监管机构——英国国家卫生与临床优化研究所(NICE)在新的指南草案中推荐将Xalkori用于特定的肺癌群体。 肺癌可分为两种,一种是非小细胞肺癌(non-smallcelllungcancer,NSCLC),另一种是小细胞癌(small cell ty...
The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of erlotinib to treat non-small cell lung cancer ( NSCLC ). The guidance recommends the use of erlotinib as an alternative to docetaxel (the standard treatment) for patients who have failed...
The aim of this study is to analyse the trends in technology appraisals for non-small cell lung cancer (NSCLC) treatments performed by the National Institute for Health and Care Excellence (NICE) over the last ten years.A systematic search was conducted for single technology appraisals of NSCLC...
The UK cost-effectiveness agency has backed Merck & Co’s Keytruda as a second-line treatment for non-small cell lung cancer, reversing its earlier position on the checkpoint inhibitor. The draft guidance from the National Insitute for Health and Care Excellence (NICE) says that adults with ...
.The article reports on the recommendation by the British National Institute for Health and Clinical Excellence (NICE) to use apixaban and systemic embolism in patients with non-valvular atrial fibrillation and its rejection of pemetrexed for non-small cell lung cancer (NSCLC)....
advanced squamous or non-squamous non-small-cell lung cancer, and an algorithm covering intrathoracic staging before radical treatment. Who is it for? Healthcare professionals Commissioners and providers People with lung cancer and their families and carers Lung cancer: diagnosis and management (NG122...
The specific recommend for Giotrif covers patients who have non-small-cell lung cancer which is locally advanced or has spread to other parts of the body. The NICE recommendation is another positive step forward for Boehringer’s relatively new oncology ambitions, which bore its first fruit with ...
The UK’s National Institute for Health and Care Excellence has authorized the use of pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer
of lung cancer for the next two years, while further data on efficacy and cost effectiveness were collected and evaluated.1 This meant that osimertinib could be used for treating locally advanced or metastatic non-small cell lung cancer expressing the epidermal growth factor receptor (EGFR) T790M ...
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute...